Your browser doesn't support javascript.
loading
Symptomatic gallstone disease: Recurrence patterns and risk factors for relapse after first admission, the RELAPSTONE study.
Velamazán, Raúl; López-Guillén, Pablo; Martínez-Domínguez, Samuel J; Abad Baroja, Daniel; Oyón, Daniel; Arnau, Anna; Ruiz-Belmonte, Lara M; Tejedor-Tejada, Javier; Zapater, Raul; Martín-Vicente, Noelia; Fernández-Esparcia, Pedro José; Julián Gomara, Ana Belén; Sastre Lozano, Violeta; Manzanares García, Juan José; Chivato Martín-Falquina, Irene; Andrés Pascual, Laura; Torres Monclus, Nuria; Zaragoza Velasco, Natividad; Rojo, Eukene; Lapeña-Muñoz, Berta; Flores, Virginia; Díaz Gómez, Arantxa; Cañamares-Orbís, Pablo; Vinzo Abizanda, Isabel; Marcos Carrasco, Natalia; Pardo Grau, Laura; García-Rayado, Guillermo; Millastre Bocos, Judith; Garcia Garcia de Paredes, Ana; Vaamonde Lorenzo, María; Izagirre Arostegi, Arantzazu; Lozada-Hernández, Edgard Efrén; Velarde-Ruiz Velasco, José Antonio; de-Madaria, Enrique.
Affiliation
  • Velamazán R; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • López-Guillén P; Department of Gastroenterology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
  • Martínez-Domínguez SJ; IIS (Instituto de Investigacion Sanitaria) Aragón, Zaragoza, Spain.
  • Abad Baroja D; Department of Gastroenterology, Hospital General Universitario Dr.Balmis, Alicante, Spain.
  • Oyón D; ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), Alicante, Spain.
  • Arnau A; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Ruiz-Belmonte LM; IIS (Instituto de Investigacion Sanitaria) Aragón, Zaragoza, Spain.
  • Tejedor-Tejada J; IIS (Instituto de Investigacion Sanitaria) Aragón, Zaragoza, Spain.
  • Zapater R; Department of Gastroenterology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Martín-Vicente N; Department of Gastroenterology, Hospital de Galdakao, Bizkaia, Spain.
  • Fernández-Esparcia PJ; Instituto de Investigación Sanitaria Biocruces, Bizkaia, Spain.
  • Julián Gomara AB; Research and Innovation Unit, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
  • Sastre Lozano V; Central Catalonia Chronicity Research Group (C3RG), Centre for Health and Social Care Research (CESS), University of Vic-Central University of Catalonia (UVIC-UCC), Vic, Spain.
  • Manzanares García JJ; Faculty of Medicine, University of Vic-Central University of Catalonia (UVIC-UCC), Vic, Spain.
  • Chivato Martín-Falquina I; Department of Gastroenterology, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Andrés Pascual L; Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain.
  • Torres Monclus N; Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Zaragoza Velasco N; Department of Gastroenterology, Hospital de Galdakao, Bizkaia, Spain.
  • Rojo E; Universidad Miguel Hernández, Elche, Spain.
  • Lapeña-Muñoz B; ISABIAL (Instituto de Investigación Sanitaria y Biomédica de Alicante), Alicante, Spain.
  • Flores V; Department of Gastroenterology, Hospital Universitario Santa Lucia, Cartagena, Spain.
  • Díaz Gómez A; Department of Gastroenterology, Hospital Universitario Santa Lucia, Cartagena, Spain.
  • Cañamares-Orbís P; Department of Gastroenterology, Hospital Universitario de Burgos, Burgos, Spain.
  • Vinzo Abizanda I; Department of Gastroenterology, Hospital Universitario de Burgos, Burgos, Spain.
  • Marcos Carrasco N; Department of Gastroenterology, Hospital Universitario Arnau de Vilanova, Lleida, Spain.
  • Pardo Grau L; Department of Gastroenterology, Hospital Universitario Arnau de Vilanova, Lleida, Spain.
  • García-Rayado G; Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid, Spain.
  • Millastre Bocos J; IIS (Instituto de Investigación Sanitaria)-Princesa, Madrid, Spain.
  • Garcia Garcia de Paredes A; Department of Gastroenterology, Hospital Universitario San Pedro, Logroño, Spain.
  • Vaamonde Lorenzo M; Department of Gastroenterology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Izagirre Arostegi A; Department of Gastroenterology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Lozada-Hernández EE; IIS (Instituto de Investigacion Sanitaria) Aragón, Zaragoza, Spain.
  • Velarde-Ruiz Velasco JA; Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario San Jorge, Huesca, Spain.
  • de-Madaria E; Specialist in Family and Community Medicine. Hospital Universitario San Jorge, Huesca, Spain.
United European Gastroenterol J ; 12(3): 286-298, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38376888
ABSTRACT

BACKGROUND:

Delayed cholecystectomy in patients with symptomatic gallstone disease is associated with recurrence. Limited data on the recurrence patterns and the factors that determine them are available.

OBJECTIVE:

We aimed to determine the pattern of relapse in each symptomatic gallstone disease (acute pancreatitis, cholecystitis, cholangitis, symptomatic choledocholithiasis, and biliary colic) and determine the associated factors.

METHODS:

RELAPSTONE was an international multicenter retrospective cohort study. Patients (n = 3016) from 18 tertiary centers who suffered a first episode of symptomatic gallstone disease from 2018 to 2020 and had not undergone cholecystectomy during admission were included. The main outcome was relapse-free survival. Kaplan-Meier curves were used in the bivariate analysis. Multivariable Cox regression models were used to identify prognostic factors associated with relapses.

RESULTS:

Mean age was 76.6 [IQR 59.7-84.1], and 51% were male. The median follow-up was 5.3 months [IQR 2.1-12.4]. Relapse-free survival was 0.79 (95% CI 0.77-0.80) at 3 months, 0.71 (95% CI 0.69-0.73) at 6 months, and 0.63 (95% CI 0.61-0.65) at 12 months. In multivariable analysis, older age (HR = 0.57; 95% CI 0.49-0.66), sphincterotomy (HR = 0.58, 95% CI 0.49-0.68) and higher leukocyte count (HR = 0.79; 95% CI 0.70-0.90) were independently associated with lower risk of relapse, whereas higher levels of alanine aminotransferase (HR = 1.22; 95% CI 1.02-1.46) and multiple cholelithiasis (HR = 1.19, 95% CI 1.05-1.34) were associated with higher relapse rates.

CONCLUSION:

The relapse rate is high and different in each symptomatic gallstone disease. Our independent predictors could be useful for prioritizing patients on the waiting list for cholecystectomies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatitis / Choledocholithiasis Limits: Aged / Female / Humans / Male Language: En Journal: United European Gastroenterol J Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatitis / Choledocholithiasis Limits: Aged / Female / Humans / Male Language: En Journal: United European Gastroenterol J Year: 2024 Document type: Article Affiliation country: Country of publication: